CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 180 enrolled
Drug / intervention
FARAPULSE Pulsed Field Ablation Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05072964
NCT05072964N/ACompleted

The FARAPULSE FARA-Freedom Trial A Prospective Open Label Single Arm Post Market Clinical Follow-Up Trial of the FARAPULSE Pulsed Field Ablation System in Patients With Paroxysmal Atrial Fibrillation

Boston Scientific Corporation·interventional·Posted Oct 11, 2021·Updated Oct 17, 2024

In Brief

A clinical study evaluating FARAPULSE Pulsed Field Ablation System for Paroxysmal Atrial Fibrillation. Completed, enrolled 180 participants across 13 sites in 6 countries.

Detailed Summary

The Post-Market Clinical Follow-Up trial is a prospective, multi-center, open-label, single-arm clinical follow-up study designed to provide long-term safety feasibility, effectiveness and performance of the FARAPULSE Pulsed Field Ablation System for the treatment of Paroxysmal Atrial Fibrillation (PAF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Czechia, Denmark, Germany, Netherlands, Switzerland
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 11, 2021
Enrollment StartDec 21, 2021
Primary CompletionOct 12, 2023
Study CompletionOct 19, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.7 years ago

Interventions

FARAPULSE Pulsed Field Ablation Systemdevice

A pulmonary vein isolation will be performed using catheter ablation